Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to present at the 5th Global Congress on Sickle Cell Disease in Abuja, Nigeria, from June 3-6, 2025. The company will showcase multiple poster presentations, including preclinical and early clinical results of Pociredir, a novel oral fetal hemoglobin inducer for treating Sickle Cell Disease, and details on a Phase 1b study evaluating the safety and pharmacokinetics of Pociredir in patients with the disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.